PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer

T Fujita, H Doihara, K Kawasaki, D Takabatake, H Takahashi, K Washio, K Tsukuda, Y Ogasawara, N Shimizu, T Fujita, H Doihara, K Kawasaki, D Takabatake, H Takahashi, K Washio, K Tsukuda, Y Ogasawara, N Shimizu

Abstract

Trastuzumab is the only HER2/neu-directed therapy to have received Food and Drug Administration approval for the treatment of patients with metastatic breast cancer. The efficacy of trastuzumab depends on the HER2/neu status of the tumour and the patient's prior treatment, but even when patients are selected on the basis of HER2/neu gene amplification, the single-agent response rate ranges from 12 to 30% and few patients respond to trastuzumab monotherapy. Here, we propose PTEN as a predictive biomarker for trastuzumab efficacy. Human breast cancer SKBR3 and drug-resistant SKBR3/R cells were investigated. We also examined clinical samples from patients who had been treated with trastuzumab and analysed the relationship between trastuzumab efficacy and PTEN level. The PI3K/Akt signalling pathway was observed to be highly active in the drug-resistant cells, and their level of PTEN was low. Delivery of antisense PTEN duplex siRNA significantly decreased the trastuzumab chemosensitivity of parental SKBR3 cells, and marked activation of Akt signalling pathway was also recognised. Moreover, immunohistochemical investigation revealed that trastuzumab treatment was remarkably successful in cells with elevated PTEN expression. Along with the immune-system-associated cytotoxic mechanism, several mechanisms have been proposed for the effect of trastuzumab. PTEN activity might play an important and major role in its HER2/PI3K/Akt-mediated antitumour effect, and could be a useful biomarker for predicting the efficacy of trastuzumab in the treatment of breast cancer.

Figures

Figure 1
Figure 1
(A) Growth inhibition assays revealed that chemosensitivity to trastuzumab was decreased in drug-resistant SKBR3/4R and /8R cells (120 h incubation with trastuzumab after 24 h incubation with medium). (B) Chemosensitivity of paclitaxel was not significantly different in drug-resistant and parental SKBR3 cells (12 h incubation with paclitaxel after 24 h incubation with medium).
Figure 2
Figure 2
The IC50 value of trastuzumab in drug-resistant SKBR3/4R cells was statistically significantly higher than in parental cells.
Figure 3
Figure 3
(A) Western blotting analysis revealed that the level of expression of the ErbB2/PI3K/Akt signal transduction pathway is the same in trastuzumab-resistant and parental cells. (B) Phosphorylated Akt activity was increased in drug-resistant SKBR3/R cells; PTEN expression was decreased in these cells.
Figure 4
Figure 4
Western blotting analysis of antisense-delivered SKBR3/WT cells showed that expression of PTEN was inhibited by duplex antisense-siRNA delivery.
Figure 5
Figure 5
The growth inhibition curve of duplex antisense-siRNA-delivered SKBR3/WT cells shows decreased trastuzumab sensitivity (120 h incubation of trastuzumab 72 h postplating).
Figure 6
Figure 6
Western blotting analysis of antisense-delivered SKBR3/WT cells showed that expression of phosphorylated Akt was increased. This suggests that Akt activity is partly due to the level of PTEN in ErbB2-overexpressing SKBR3 cells.
Figure 7
Figure 7
The growth inhibition rate of paclitaxel in antisense-delivered SKBR3/WT cells. No significant difference was observed for the growth inhibition effect of paclitaxel between antisense- and control oligonucleotide-delivered cells (12 h incubation of paclitaxel 72 h postplating).
Figure 8
Figure 8
PTEN expression pattern in human breast tumours. ErbB2-overexpressing primary breast carcinomas from 17 patients who subsequently received trastuzumab plus pacliataxel were analysed. PTEN expression of these tumours was examined by IHC and semiquantified using immunoreactive scores. Representative tumour PTEN stainings (IRS 3+, 2+, 1+, and −).
Figure 9
Figure 9
Immunohistochemical investigation of PTEN expression from patients with erbB2-overexpressing breast cancer treated with trastuzumab. We analysed 17 breast cancer tissue samples by immunohistochemistry. In those cases with increased PTEN expression (3+, 2+), the efficacy of trastuzumab-containing chemotherapy was remarkable and the response rate statistically significant (statistical analysis was performed with Fisher's test).

References

    1. Albanell J, Baselga J (2001) Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect. J Natl Cancer Inst 93: 1830–1832
    1. Bose S, Wang SI, Terry MB, Hibshoosh H, Parsons R (1998) Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas. Oncogene 17: 123–127
    1. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS, Sidransky D (1997) Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 57: 4997–5000
    1. Carraway H, Hidalgo M (2004) New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res 6: 219–224
    1. Chui X, Egami H, Yamashita J, Kurizaki T, Ohmachi H, Yamamoto S, Ogawa M (1996) Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues. Br J Cancer 73: 1233–1236
    1. Crowder RJ, Lombardi DP, Ellis MJ (2004) Successful targeting of ErbB2 receptor – is PTEN the key? Cancer Cell 6: 103–104
    1. Depowski PL, Rosenthal SI, Ross JS (2001) Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol 14: 672–676
    1. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP (1998) Pten is essential for embryonic development and tumour suppression. Nat Genet 19: 348–355
    1. Downward J (1998) Ras signaling and apoptosis. Curr Opin Genet Dev 8: 49–54
    1. Feilotter HE, Coulon V, McVeigh JL, Boag AH, Dorion-Bonnet F, Duboue B, Latham WC, Eng C, Mulligan LM, Longy M (1999) Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma. Br J Cancer 79: 718–723
    1. Friedrichs K, Gluba S, Eidtmann H, Jonat W (1993) Overexpression of p53 and prognosis in breast cancer. Cancer 72: 3641–3647
    1. Garcia JM, Silva JM, Dominguez G, Gonzalez R, Navarro A, Carretero L, Provencio M, Espana P, Bonilla F (1999) Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res Treat 57: 237–243
    1. Li DM, Sun H (1998) PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci USA 95: 15406–15411
    1. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943–1947
    1. Louis DN, Gusella JF (1995) A tiger behind many doors: multiple genetic pathways to malignant glioma. Trends Genet 11: 412–415
    1. Lu Y, Lin YZ, LaPushin R, Cuevas B, Fang X, Yu SX, Davies MA, Khan H, Furui T, Mao M, Zinner R, Hung MC, Steck P, Siminovitch K, Mills GB (1999) The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene 18: 7034–7045
    1. Lu Y, Zi X, Pollak M (2004) Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 108: 334–341
    1. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M (2001) Insulin-like growth factor-1 receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93: 1852–1857
    1. Menendez JA, Vellon L, Lupu R (2005) Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells. Med Hypotheses 64: 997–1001
    1. Meuillet EJ, Ihle N, Baker AF, Gard JM, Stamper C, Williams R, Coon A, Mahadevan D, George BL, Kirkpatrick L, Powis G (2004) In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316. Oncol Res 14(10): 513–527
    1. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, Weng LP, Eng C (2000) Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 92: 924–930
    1. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen N, Hortobagyi GN, Hung MC, Yu D (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117–127
    1. Nahta R, Esteva FJ (2004) In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells. Cancer Chemother Pharmacol 53: 186–190
    1. Pandolfi PP (2004) Breast cancer – loss of PTEN predicts resistance to treatment. N Engl J Med 351: 2337–2338
    1. Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PL, Komminoth P, Lees JA, Mulligan LM, Mutter GL, Eng C (1999) Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 155: 1253–1260
    1. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE, Parsons R (1999) Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 96: 1563–1568
    1. Risinger J, Hayes AK, Berchuck A, Barrett JC (1997) PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 57: 4736–4738
    1. Singh B, Ittmann MM, Krolewski JJ (1998) Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus. Genes Chromosomes Cancer 21: 166–171
    1. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, Li J, Parsons R, Ellenson LH (1997) Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 57: 3935–3940
    1. Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, Swedlund B, Hansen KL, Vinson VL, Gumpper KL, Ellis L, EL-Naggar A, Frazier M, Jasser S, Langford LA, Lee J, Mills GB, Pershouse MA, Pollack RE, Tornos C, Troncoso P, Yung WK, Fujii G, Berson A, Steck PA et al (1997) MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 57: 5221–5225
    1. Torres J, Pulido R (2001) The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. J Biol Chem 276: 993–998
    1. Vogel CL, Reddy JC, Reyno LM (2005) Efficacy of trastuzumab. Cancer Res 65: 2044.
    1. Yu D, Hung MC (2000) Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 19: 6115–6121

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera